Life Sciences

Court dismisses off-label suit against Amgen

Pharma Compliance Alert, December 31, 2008

Amgen will not have to face a lawsuit from seven small health benefit plans that claimed the company improperly promoted its anemia drugs.

The U.S. District Court for the Central District of California dismissed the suit as an improper attempt to privately enforce the Food, Drug, and Cosmetic Act, according to a Reuters article. The court also ruled the plaintiffs needed to reference specific misrepresentations made by Amgen and two kidney dialysis providers.


0 comments on “Court dismisses off-label suit against Amgen